Is Pelacarsen delayed???

[anonymous]

It’s not just delayed, it’s done. They pushed back the study which most likely means the outcomes are not significant enough to stop trial early. If and when it’s ever launched, other products with better efficacy and better dosing will also be available.

At least 2 reasons, that Pelacarsen will not replace Entresto, theory and patients are wrong, lp(a) reduction should start in young age, obese after decades have cholesterol crystals everywhere, that will not disappear with Pelacarsen and result in chronic inflammation based cardiovascular events. In addition, we pushed the lp(a) story, and now several studies included lp(a) in trials with GLP1 agonists, and some of them showed statistical reductions of lp(a) over 50%.

 

[anonymous]

It’s not just delayed, it’s done. They pushed back the study which most likely means the outcomes are not significant enough to stop trial early. If and when it’s ever launched, other products with better efficacy and better dosing will also be available.

Delays can happen in drug development. It however seems to be happening again and again at Novartis. Nothing ever launches on time or on budget. Why is it do difficult? Why are leaders never held accountable?